Melbourne Researchers Pioneer Phage Therapy to Combat Life-Threatening Superbugs Amid Rising Global Antimicrobial Resistance

Researchers at Monash University and The Alfred identify immune barriers in phage therapy, paving the way for personalized treatments for resistant infections.

By: AXL Media

Published: Apr 24, 2026, 6:57 AM EDT

Source: Information for this report was sourced from EurekAlert

A New Frontier in Melbourne’s Infectious Disease Treatment

Medical researchers in Melbourne have launched a pioneering clinical initiative aimed at treating life-threatening infections through the use of bacteriophages. Known as VICPhage, this partnership between The Alfred and Monash University provides a comprehensive framework for phage therapy, a process that involves injecting patients with specific viruses designed to target and eliminate bacterial pathogens. According to Professor Anton Peleg, the service is currently being utilized for compassionate-use cases where patients have exhausted all standard antibiotic options.

Resurrecting a Century Old Medical Concept

While the use of phages to treat disease dates back to the early 1900s, the practice was largely abandoned following the widespread introduction of modern antibiotics. However, as antimicrobial resistance becomes a more urgent global threat, scientists are returning to these biological alternatives. According to the research team, contemporary innovations in technology now allow for a more sophisticated application of this therapy, transforming a historical concept into a precise, personalized medical tool capable of addressing multidrug-resistant pathogens.

Lessons from Victoria’s First Phage Therapy Case

A recent study published in Nature Medicine details the first ever phage therapy case performed in Victoria, involving a 22-year-old cystic fibrosis patient with severe, recurrent infections. Despite the precision of the bacteriophages used, the treatment did not achieve the desired outcome. According to Dr. Fernando Gordillo-Altamirano, the investigation into this failure revealed that the patient possessed pre-existing antibodies that neutralized the phages before they could reach the bacteria. This discovery provides a vital roadmap for screening future patients to ensure the selected phages are compatible with their immune systems.